Karlee Phillips

Karlee Phillips is a multimedia journalist who grew up in Sioux City, Iowa. She graduated from East High in 2020 and went on to study Media and Journalism at the University of South Dakota. During her time at USD, she was involved in various student media groups including Coyote News TV, KAOR Radio, and The Volante newspaper. Karlee received several awards for her work in radio and television, including the Eric Sevareid Award of Merit for 'Best Student Market Radio Newscast' and a National Academy of Television Arts and Sciences Student Award for her PSA about agriculture in the Midwest. She graduated from USD in December 2023 with a B.A. in Media and Journalism and minors in Business Administration and Spanish, then joined the KELOLAND team later that month. Karlee is also a runner, thrift shop enthusiast, dog lover, Kate Spade fan, and admirer of Seinfeld quotes.

85%

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

50%

Examples:

  • The article does not present any opposing viewpoints or counterarguments, which could give the reader a more balanced perspective on postpartum depression and anxiety.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

50%

Examples:

  • The article states that up to 90% of women experience postpartum blues, but then it also says that postpartum depression affects up to 1 in 5 women. These two statements seem contradictory.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Hope in Treating Postpartum Depression: The Role of Zuranolone (Zurzuvae)

New Hope in Treating Postpartum Depression: The Role of Zuranolone (Zurzuvae)

Broke On: Tuesday, 21 May 2024 Zuranolone, the first pill designed to treat postpartum depression (PPD), offers hope for new mothers suffering from this common yet often overlooked mental health condition. With promising results in clinical trials and FDA approval in August 2023, this neurosteroid medication can alleviate symptoms such as anxiety, difficulty sleeping, and low energy within three days. However, despite increased awareness and advancements in treatment options like Zuranolone, many women still face barriers when seeking help for PPD. Healthcare providers play a crucial role in identifying at-risk women and ensuring they receive appropriate care to overcome these barriers.